Evaluation of PRDM1 gene polymorphism with hepatitis C virus-related hepatocellular carcinoma in a cohort of Egyptian patients | ||||
| Azhar International Journal of Pharmaceutical and Medical Sciences | ||||
| Article 10, Volume 3, Issue 1, January 2023, Page 105-111 PDF (253.56 K) | ||||
| Document Type: Original research articles | ||||
| DOI: 10.21608/aijpms.2022.151773.1154 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Aya M Ibrahim  1; Amal A Mohamed2; Omnia E Esmail1; Amir Khater3; Rehab R. El-Awady4
| ||||
| 1Department of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt | ||||
| 2Department of Biochemistry National Hepatology and Tropical Medicinal Research Institute, Cairo, Egypt | ||||
| 3Department National Hepatology, Internal Medicine and Tropical Medicine Research Institute, Cairo, Egypt | ||||
| 4Department of Biochemistry and Molecular Biology, Faculty of Pharmacy (Girls), Al-Azhar University, Egypt, | ||||
| Abstract | ||||
| Abstract The third most common cancer-related cause of death worldwide is hepatocellular carcinoma (HCC). and it is the sixth most common primary malignancy overall. Egypt had the hepatitis C virus’s highest prevalence (HCV). A critical topic of study is the association between HCV and HCC. PR domain zinc finger protein 1(PRDM1) functions as a tumor suppressor in B and T cells and is critical for plasma cell development and the exhaustion of T lymphocytes caused by cancer and chronic viral infections. Aim: This study aimed to compare Egyptian patients with HCC to a control group to determine the allele frequencies and genotype of the rs1010273 PRDM1 gene polymorphism. Method: 200 Egyptian patients (100 HCC and 100 control). All participants underwent laboratory evaluations, comprising hepatitis markers (HBsAg, anti-HCV-Ab), liver function tests, serum alpha-fetoprotein, and complete blood count. Using the TaqMan allelic discrimination assay method, the PRDM1 rs1010273 was genotyped. Results: Unlike healthy controls, the HCC patients had a greater frequency of the GA genotype (43% vs. 20%) and the A allele (26.5% vs. 10%). A significant difference was found between the GA and A allele of PRDM1 genotype of HCC patients and controls (P<.001). Conclusion: A statistically significant and greater frequency of the A allele and GA genotype was found in HCC patients compared to controls, indicating a relationship between the PRDM1 AA+GA gene polymorphism and the HCC Egyptian population. The A allele was assumed to be a risk factor for HCC (OR=11.212). SNP (rs1010273G/A) may be an optional valuable marker. | ||||
| Keywords | ||||
| PRDM1; Genotype; HCC; Polymorphism; HCV | ||||
|
Statistics Article View: 208 PDF Download: 231 |
||||
